Physician profile
Surendar Chima
NPI 1144235540
$568.30
in general payments reported to CMS, 2019-2025
10 companies · $18.65 in 2025
The $18.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.32 · 2020: $37.79 · 2021: $211 · 2022: $16.91 · 2023: $230 · 2024: $42.71 · 2025: $18.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $81.45 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $78.64 | 2019-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $53.65 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $44.56 | 2021-2023 | Rotateq, Vaxneuvance, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $41.57 | 2020-2023 | Abilify Maintena, Rexulti |
| Glaxosmithkline, LLC. | $39.20 | 2022-2023 | Shingrix, Pediarix, Bexsero |
| Alkermes, INC. | $25.00 | 2020 | |
| Neurocrine Biosciences, INC. | $16.93 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendar Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.